Volume : 08, Issue : 09, September – 2021

Title:

05.A SURVEY TO ASSESS THE IMPACT OF UTERINE FIBROIDS AMONG WOMEN IN BATHINDA REGION

Authors :

Kaur Shubhdeep, Kaur Ramanjeet, Patil R.K., Kaur Hashmeet, Patil H.C

Abstract :

A uterine fibroid is a widespread benign(non– cancerous) tumor of smooth muscle of the uterus. They are the most common pelvic tumor in women of childbearing age, and in at least 50% of affected womenare asymptomatic. The aim and objective of the study was to assess the quality of life of women’s with symptomatic uterine fibroids and to assess the knowledge regarding uterine fibroids among women. The study was conducted at Department of gynecology at Adesh Hospital, Bathinda. The duration of the study was 3 months. The study was started after getting approval from AIPBS, Departmental Research Committee Adesh University, Bathinda, Punjab. The confidence interval was of the study was selected as 95% and the sample size was calculated through epi info. Overall, 112 participates were enrolled in the study as per sample size. Women of age group 30-45 years with uterine fibroids and complaints of heavy menstrual bleeding and other symptoms were included as cases. After a written informed consent form, a self-made questionnaire was used to collect information about severity of symptoms, due to uterine fibroids. The recorded data will be analyzed as per objectives of the study and the data analysis was done using MS.excel. Uterine fibroids causing several menstrual symptoms (heavy bleeding with blood clots, prolonged and frequent periods, irregular /Unpredictable periods) and bladder and bowel symptoms (frequent urination during the daytime, frequent urination during the nighttime, pressure or tightness in pelvic area) that can have negative impact on quality of women’s life. Patients feel weakness /fatigue, sad, discouraged or hopeless and felt stressful and embarrassment due to this disease condition which a result interferes daily activity.
Key-words: Menstrual symptoms, bladder and bowel symptoms, Anemia, Infertility, Quality of life, Uterine fibroids,

Cite This Article:

Please cite this article in press Kaur Ramanjeet et al., A Survey To Assess The Impact Of Uterine Fibroids Among Women In Bathinda Region.., Indo Am. J. P. Sci, 2021; 08(09).

Number of Downloads : 10

References:

1. http://www.medicinet.com/uterine_fibroids/ disscussion-269.htm.
2. Philip Thomason.Leiomyoma, Uterus (Fibroid) [online].2008 May 6.Available from: URL: http://emedicine.medscape.com/article/405676- overview.
3. Goto A, Takeuci s, Sugimura K, Maruo T. “usefulness of Gd-DTPA contrast-enchansed dynamic MRI and Serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus”. Int. J. Gynecol. Cancer 12 (4): 354-61.
4. Krysiewicz, S., Infertility in women: diagnostic evaluation with hysterosalpingography and other imaging techniques. American Journal of Roentgenology, 1992. 159(2): p. 253-261.
5. Murase, E., et al., Uterine Leiomyomas: Histopathologic Features, MR Imaging Findings, differential Diagnosis, and Treatment1. Radiographics, 1999. 19(5): p. 1179-1197.
6. Ahmadi, F., et al., Uterine Leiomyoma: Hysterosalpingographic Appearances. International Journal of Fertility and Sterility, 2008. 1(4): p. 137-144
7. Walker, C.L. and E.A. Stewart, Uterine fibroids: the elephant in the room. Science, 2005. 308(5728): p. 1589-1592.
8. Islam, M.S., et al., Uterine leiomyoma: available medical treatments and new possible therapeutic options. Journal of Clinical Endocrinology & Metabolism, 2013. 98(3): p. 921–934.
9. Maruo, T., et al., Sex steroidal regulation of uterine leiomyoma growth and apoptosis.Human Reproduction Update, 2004. 10(3): p. 207-20.
10. Ciarmela, P., et al., Growth factors and myometrium: biological effects in uterine fibroid and Possible clinical implications. Human Reproduction Update, 2011. 17(6): p. 772-790.
11. Kim, J.J. and E.C. Sefton, The role of progesterone signaling in the pathogenesis of uterine Leiomyoma. Molecular and Cellular Endocrinology, 2011. 358(2): p. 223-31.
12. Chegini, N., Proinflammatory and profibrotic mediators: principal effectors of leiomyoma Development as a fibrotic disorder. Seminars in Reproductive Medicine, 2010. 28(3): p. 180-203.
13. Flake, G.P., J. Andersen, and D. Dixon, Etiology and pathogenesis of uterine leiomyomas: a Review. Environmental Health Perspectives, 2003. 111(8): p. 1037-54.
14. Ciarmela, P., et al., Activin-A and Myostatin Response and Steroid Regulation in Human Myometrium: Disruption of Their Signalling in Uterine Fibroid. Journal of Clinical Endocrinology & Metabolism, 2011a. 96(03): p. 755-65.
15. Ciarmela, P., E. Wiater, and W. Vale, Activin-A in myometrium: characterization of the Actions on myometrial cells. Endocrinology, 2008. 149(5): p. 2506-16.
16. Ciarmela, P., et al., Presence, actions, and regulation of myostatin in rat uterus and Myometrial cells. Endocrinology, 2009. 150(2): p. 906-14.
17. Sozen, I. And A. Arici, Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata. Fertility and Sterility, 2002. 78(1): p. 1-12.
18. Hatthachote, P. And J.I. Gillespie, Complex interactions between sex steroids and cytokines in the human pregnant myometrium: evidence for an autocrine signaling system at term.Endocrinology, 1999. 140(6): p. 2533-40.
19. Litovkin, K.V., et al., Interleukin-6 -174G/C polymorphism in breast cancer and uterine Leiomyoma patients: a population-based case control study. Experimental Oncology, 2007. 29(4): p. 295-98.
20. Luo, X., et al., Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta. Endocrinology, 2005. 146(3): p. 1097-1118.
21. Ding, L., X. Luo, and N. Chegini, The expression of IL-13 and IL-15 in leiomyoma and Myometrium and their influence on TGF-β and proteases expression in leiomyoma and Myometrial smooth muscle cells and SKLM, leiomyosarcoma cell line. Journal of the Society for Gynecologic Investigation, 2004. 11: p. 319A.
22. Kurachi, O., et al., Tumor necrosis factor-α expression in human uterine leiomyoma and its down -regulation by progesterone. Journal of Clinical Endocrinology & Metabolism, 2001.86(5): p. 2275-2280.
23. Syssoev, K.A., et al., Expression of mRNA for chemokines and chemokine receptors in tissues of the myometrium and uterine leiomyoma. Bulletin of Experimental Biology and Medicine, 2008. 145(1): p. 84-89.
24. Sozen, I., D.L. Olive, and A. Arici, Expression and hormonal regulation of monocyte Chemotactic protein-1 in myometrium and leiomyomata. Fertility and Sterility, 1998. 69(6): P. 1095-1102.
25. Malik, M., et al., Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women. Seminars in Reproductive Medicine, 2010. 28(3): p. 169-179.
26. Wolanska, M., et al., Extracellular matrix components in uterine leiomyoma and their Alteration during the tumour growth. Molecular and cellular biochemistry, 1998. 189(1): p. 145-52.
27. Arici, A. And I. Sozen, Transforming growth factor-beta3 is expressed at high levels in Leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertility and Sterility, 2000. 73(5): p. 1006-1011.
28. Norian, J.M., et al., Transforming growth factor beta3 regulates the versican variants in the Extracellular matrix-rich uterine leiomyomas. Reproductive Sciences, 2009. 16(12): p. 1153-1164.
29. Evans, P. And S. Brunsell,Uterine fibroid tumors: diagnosis and treatment. Am Fam Physician, 2007.75(10):p. 1503-8.
30. Baird,D.D.,etal.,High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. American Journal of Obstetrics and Gynecology, 2003.188(1):p.100-7.
31. Ligon, A.H. and C.C. Morton, Genetics of uterine leiomyomata. Genes Chromosomes Cancer, 2000.28(3):p.235-45.
32. D’Aloisio,A.A.,et al., Association of intrauterine and early-life exposures with diagnosis of Uterine leiomyomata by 35 years of age in the Sister Study. Environ Health Perspect, 2010. 118(3): p.375-81.
33. Chen, C.R.,etal.,Risk factors for uterine fibroids among women undergoing tubal Sterilization. Am J Epidemiol, 2001.153(1):p.20-6
34. Wise,L.A.,etal.,Reproductivefactors,hormonal contraception, and risk of uterine Leiomyomata in African-American women: a prospective study. Am J Epidemiol, 2004. 159(2): p.113 23.
35. Templeman, C.,et al., Risk factors for surgically removed fibroids in a large cohort of Teachers. FertilSteril, 2009.92(4):p.1436-46.
36. Terry, K.L.,etal.,Anthropometric characteristics and risk of uterine leiomyoma.Epidemiology, 2007.18(6):p.758-63.
37. http://www.womenshealth.gov/FAQ/uterine fibroids.cfm
38. http://www.fibroidtumors.net
39. American Society of Reproductive Medicine Patient Booklet: Uterine Fibroids,2003.
40. Uterine Fibroids- The Merck Manuals Online Medical Library.
41. Eder,S.,etal.,Efficacy and safety of oral tranexamic acid in women with heavy menstrual bleeding and fibroids. Womens Health (LondEngl), 2013.9(4):p.397-403.
42. Lethaby,A.,K. Duckitt, and C.Farquhar,Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev, 2013.1:p. Cd000400.
43. Engman M, Granberg S, Willians ARW, Meng CX, Lalitkumar PGL, Gemzell-Danielsson k (August 2009).”Mifepristone for treatmebt of Uterine Leiomyoma. A Prospective Randomized Placebo Controlled Trial”, Human Reproduction 24 (8): 1870-9.
44. http:/www.babycenter.in/preconception/suscep-tingaproblem/fibroid.
45. Polena, V ., et al. “Long-term results of hysteroscopic myomectomy I 235 patients.”European journal of Obstetrics and Gynecology and Reproductive Biology. 130 (2007): 232-237.
46. Agdi M, and Tulandi T. “Endoscopic management of Uterine fibroids.” Best Practice and Research Clinical Th Obstetrics and Gynecology, online publication Mar 2008.
47. Wallach EE, Vlahos NF.”Uterinemyomas: an overview of development, clinical features, and management”. ObstetGynecol 104 (2004), pp. 393- 406.